Exane Derivatives’s ADMA Biologics ADMA Stock Holding History

Exane Derivatives’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-1,299	Closed	-$2.38K	–	766
2022 Q1	$2.38K	Sell	1,299 -27,049	-95%	-$42.2K	﹤0.01%	740
2021 Q4	$40K	Buy	+28,348	New	+$37.3K	0.01%	525
2021 Q1	–	Sell	-1,517	Closed	-$2.96K	–	887
2020 Q4	$2.96K	Hold	1,517	–	–	﹤0.01%	594
2020 Q3	$3.63K	Sell	1,517 -27,036	-95%	-$74.1K	﹤0.01%	527
2020 Q2	$83.7K	Buy	+28,553	New	+$82K	0.02%	316

Other funds holding ADMA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

AIC

AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return

Exane Derivatives's ADMA Position: Q2 2022 in Review

Exane Derivatives sold out of ADMA Biologics (ADMA) in Q2 2022, closing a stake of 1,299 shares — an estimated $2.38K sold.

Exane Derivatives first reported a position in ADMA in Q2 2020 and held it in 5 quarters. The position peaked at $83.7K in Q2 2020. 113 funds tracked by Wall St. Rank hold ADMA as of Q2 2022.

Exane Derivatives reported no remaining ADMA Biologics position as of Q2 2022 after selling out during the quarter.
Exane Derivatives sold 1,299 ADMA Biologics shares in Q2 2022, an estimated $2.38K.
Exane Derivatives first reported a position in ADMA Biologics in Q2 2020 and held it in 5 quarters.
Exane Derivatives's ADMA Biologics position peaked at $83.7K in Q2 2020.
113 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2022.

Based on Exane Derivatives's 13F filing for Q2 2022, filed 12 Jul 2022.